GLOBAL

Our Share price may be volatile, which could result in substantial losses for investorspurchasing Shares in this InvitationPrior to this Invitation, our Shares could not be bought or sold publicly. An active public market for ourShares may not develop or be sustained following this Invitation. You may be unable to sell yourShares at or above the Issue Price. The market price of our Shares may fluctuate significantly andrapidly as a result of, inter alia, the following factors, some of which are beyond our control:±. Changes in our operating results;. Changes in securities analysts' estimates of our financial performance;. Changes in market valuations of similar companies;. Announcements by us or our competitors of gain or loss of significant contracts, acquisitions,strategic partnerships, joint ventures or capital commitments;. Additions or departures of key personnel;. Fluctuations in stock market price and volume; and. Involvement in litigation.New Investors in our Company will incur immediate dilutionThe issue price of our Shares is substantially higher than the NTA per Share based on the postInvitation issued share capital. If we were to be liquidated for NTA immediately following thisInvitation, each shareholder subscribing to this Invitation would receive less than the price they paidfor their Shares. Details of the immediate dilution of our Shares incurred by new Investors aredescribed under the heading ``Dilution'' on page 55 of this Prospectus.Our Directors and controlling shareholders will retain signi®cant control over the Company afterthe Invitation, which will allow them to in¯uence the outcome of matters submitted toshareholders for approvalUpon completion of this Invitation, our Directors (namely Cynthia Poa Kheng Bee and Serene Ali Tanwho own the entire share capital of Healthcare) and our controlling shareholders (namely Healthcareand Osim who hold 41.51% and 23.92% respectively, of the enlarged issued capital of our Companyimmediately after the Invitation) will bene®cially own an aggregate of 65.43% of the enlarged issuedshare capital of our Company. As a result, these persons, if they act in concert, will be able to exercisesigni®cant in¯uence over all matters requiring shareholders' approval, including the election andremoval of Directors, the approval of any business transaction, and will possess the veto power withrespect to any shareholder action or approval requiring a majority vote. This may have the effect ofdelaying, preventing or deterring a change in control which may bene®t our shareholders.34